PPARG and metabolic dysfunction-associated steatohepatitis: Antihyperglycemic drugs, such as pioglitazone, a potent ligand of PPARγ, delay liver fibrosis and hepatocarcinogenesis in dietary NASH models and DEN-treated mice by enhancing AMPK pathways and mitobiogenesis [239].